Shots:
- The CHMP grants a positive opinion to Akantior for treating acanthamoeba keratitis based on the P-I & P-III studies. The final decision is anticipated in Aug 2024, to be valid across the EU incl. Iceland, Liechtenstein & Norway
- The P-I trial determined the effect of different polihexanide concentrations vs PBO among healthy individuals (n=90) and verified that polihexanide (0.8mg/ml) had no significant differences in AEs vs PBO
- The P-III (Study 043/SI) trial of polihexanide (0.8mg/ml or 0.08%) in acanthamoeba keratitis adults & adolescents (n=135) showed 86.7% of clinical resolution rate with 4mos. median time to cure plus improved vision & QoL
Ref:Sifi | Image:Sifi | Press Release
Related News:- Johnson & Johnson Gains the CHMP’s Positive Opinion for Rybrevant (Amivantamab) as a 1L Treatment of NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
